Isolation of melanoma cell subpopulations using negative selection

Por Slipicevic, Ana, Somasundaram, Rajasekharan, Sproesser, Katrin, Herlyn, Meenhard
Publicado no Methods Mol Biol (2014)

Targeting RRM2 and Mutant BRAF is a Novel Combinatorial Strategy for Melanoma

Por Fatkhutdinov, Nail, Sproesser, Katrin, Krepler, Clemens, Liu, Qin, Brafford, Patricia A., Herlyn, Meenhard, Aird, Katherine M., Zhang, Rugang
Publicado no Mol Cancer Res (2016)

Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice

Por Wondimu, Assefa, Zhang, Tianqian, Kieber-Emmons, Thomas, Gimotty, Phyllis, Sproesser, Katrin, Somasundaram, Rajasekharan, Ferrone, Soldano, Tsao, Chun-Yen, Herlyn, Dorothee
Publicado em 2008

PLX4032, a Potent Inhibitor of the B-Raf V600E Oncogene, Selectively Inhibits V600E-positive Melanomas

Por Lee, John T., Li, Ling, Brafford, Patricia A., van den Eijnden, Marcia, Halloran, Molly B., Sproesser, Katrin, Haass, Nikolas K., Smalley, Keiran S.M., Tsai, James, Bollag, Gideon, Herlyn, Meenhard
Publicado em 2010

Oncogenic BRAF-mediated Melanoma Cell Invasion

Por Lu, Hezhe, Liu, Shujing, Zhang, Gao, Kwong, Lawrence N., Zhu, Yueyao, Miller, John P., Hu, Yi, Zhong, Wenqun, Zeng, Jingwen, Wu, Lawrence, Krepler, Clemens, Sproesser, Katrin, Xiao, Min, Xu, Wei, Karakousis, Giorgos C., Schuchter, Lynn M., Field, Jeffery, Zhang, Paul J., Herlyn, Meenhard, Xu, Xiaowei, Guo, Wei
Publicado no Cell Rep (2016)

Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models identify second line combination therapies

Por Krepler, Clemens, Xiao, Min, Sproesser, Katrin, Brafford, Patricia, Shannan, Batool, Beqiri, Marilda, Liu, Qin, Xu, Wei, Garman, Bradley, Nathanson, Katherine L., Xu, Xiaowei, Karakousis, Giorgos, Mills, Gordon B., Lu, Yiling, Ahmed, Tamer A., Poulikakos, Poulikos I., Caponigro, Giordiano, Boehm, Markus, Peters, Malte, Schuchter, Lynn M., Weeraratna, Ashani T., Herlyn, Meenhard
Publicado no Clin Cancer Res (2015)

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma

Por Villanueva, Jessie, Infante, Jeffrey R., Krepler, Clemens, Reyes-Uribe, Patricia, Samanta, Minu, Chen, Hsin-Yi, Li, Bin, Swoboda, Rolf K., Wilson, Melissa, Vultur, Adina, Fukunaba-Kalabis, Mizuho, Wubbenhorst, Bradley, Chen, Thomas Y., Liu, Qin, Sproesser, Katrin, DeMarini, Douglas J., Gilmer, Tona M., Martin, Anne-Marie, Marmorstein, Ronen, Schultz, David C., Speicher, David W., Karakousis, Giorgos C., Xu, Wei, Amaravadi, Ravi K., Xu, Xiaowe, Schuchter, Lynn M., Herlyn, Meenhard, Nathanson, Katherine L.
Publicado em 2013

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Por Tsai, James, Lee, John T., Wang, Weiru, Zhang, Jiazhong, Cho, Hanna, Mamo, Shumeye, Bremer, Ryan, Gillette, Sam, Kong, Jun, Haass, Nikolas K., Sproesser, Katrin, Li, Ling, Smalley, Keiran S. M., Fong, Daniel, Zhu, Yong-Liang, Marimuthu, Adhirai, Nguyen, Hoa, Lam, Billy, Liu, Jennifer, Cheung, Ivana, Rice, Julie, Suzuki, Yoshihisa, Luu, Catherine, Settachatgul, Calvin, Shellooe, Rafe, Cantwell, John, Kim, Sung-Hou, Schlessinger, Joseph, Zhang, Kam Y. J., West, Brian L., Powell, Ben, Habets, Gaston, Zhang, Chao, Ibrahim, Prabha N., Hirth, Peter, Artis, Dean R., Herlyn, Meenhard, Bollag, Gideon
Publicado em 2008

Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors

Por Zhang, Gao, Frederick, Dennie T., Wu, Lawrence, Wei, Zhi, Krepler, Clemens, Srinivasan, Satish, Chae, Young Chan, Xu, Xiaowei, Choi, Harry, Dimwamwa, Elaida, Ope, Omotayo, Shannan, Batool, Basu, Devraj, Zhang, Dongmei, Guha, Manti, Xiao, Min, Randell, Sergio, Sproesser, Katrin, Xu, Wei, Liu, Jephrey, Karakousis, Giorgos C., Schuchter, Lynn M., Gangadhar, Tara C., Amaravadi, Ravi K., Gu, Mengnan, Xu, Caiyue, Ghosh, Abheek, Xu, Weiting, Tian, Tian, Zhang, Jie, Zha, Shijie, Liu, Qin, Brafford, Patricia, Weeraratna, Ashani, Davies, Michael A., Wargo, Jennifer A., Avadhani, Narayan G., Lu, Yiling, Mills, Gordon B., Altieri, Dario C., Flaherty, Keith T., Herlyn, Meenhard
Publicado no J Clin Invest (2016)